pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Outcomes of users of rivaroxaban vs. warfarin

Rivaroxaban user (n=1,079) Matched warfarin user (n=1,079) Hazard Ratio(95% CI)


Events(%) Person-years(PYs) IR/100PYs Events(%) Person-years(PYs) IR/100PYs
MACCE 13(1.20) 346.38 3.75 30(2.78) 673.74 4.45 0.72(0.36-1.45)
Ischemic stroke/systemic embolism 2(0.19) 348.15 0.57 5(0.46) 683.73 0.73 0.74(0.43-1.28)
Myocardial infarction 7(0.65) 347.31 2.02 16(1.48) 678.76 2.36 0.65(0.26-1.64)
Cardiac death 4(0.37) 348.01 1.15 9(0.83) 682.39 1.32 0.72(0.21-2.51)
Bleeding 28(2.59) 343.44 8.15 37(3.43) 669.65 5.53 1.25(0.74-2.11)
Intracranial bleeding 2(0.19) 348.37 0.57 8(0.74) 682.55 1.17 0.45(0.09-2.16)
Gastrointestinal bleeding 26(2.41) 343.62 7.57 31(2.87) 672.01 4.61 1.43(0.81-2.51)

MACCE, major adverse cerebro-cardiovascular events; IR, incidence rate; PY, person-years; CI, confidence interval

Korean J Clin Pharm 2022;32:37-46 https://doi.org/10.24304/kjcp.2022.32.1.37
© 2022 Korean J Clin Pharm